Acción AXIM AXIM BIOTECHNOLOGIES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas AXIM Biotechnologies, Inc.

Acciones

AXIM

US05463V1008

Diferido OTC Markets
Otros sitios de cotización
 15:41:08 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,0116 USD -4,59 % Gráfico intradía de AXIM Biotechnologies, Inc. +6,42 % -38,95 %
16/04 AXIM Biotechnologies, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI
20/02 La plataforma de pruebas basadas en lágrimas de AXIM Biotechnologies, Inc sigue ganando adeptos tras su exitosa validación clínica CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción AXIM
  4. Noticias AXIM Biotechnologies, Inc.
  5. Otros idiomas